Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A DRUG-INTERACTION STUDY BETWEEN TICLOPIDINE AND CYCLOSPORINE IN HEART-TRANSPLANT RECIPIENTS
Autore:
BOISSONNAT P; DELORGERIL M; PERROUX V; SALEN P; BATT AM; BARTHELEMY JC; BROUARD R; SERRES E; DELAYE J;
Indirizzi:
CHU NORD,LAB PHYSIOL EXPLORAT FONCT CARDIORESP,NIVEAU 6 F-42055 ST ETIENNE 2 FRANCE CHU NORD,LAB PHYSIOL EXPLORAT FONCT CARDIORESP F-42055 ST ETIENNE 2 FRANCE HOP CARDIOVASC,SERV CARDIOL B F-69003 LYON FRANCE FAC PHARMACEUT SCI,CTR MEDICAMENT,CNRS URA 597 NANCY FRANCE SANOFI RECH F-34082 MONTPELLIER FRANCE
Titolo Testata:
European Journal of Clinical Pharmacology
fascicolo: 1, volume: 53, anno: 1997,
pagine: 39 - 45
SICI:
0031-6970(1997)53:1<39:ADSBTA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIPID-LOWERING AGENT; PLATELET-AGGREGATION; PHARMACOKINETICS; 6-BETA-HYDROXYCORTISOL; FENOFIBRATE; INDUCTION; THERAPY; DISEASE; ASPIRIN;
Keywords:
TICLOPIDINE; CYCLOSPORINE; HEART TRANSPLANTATION; CYTOCHROME P450-3A4; DRUG INTERACTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
P. Boissonnat et al., "A DRUG-INTERACTION STUDY BETWEEN TICLOPIDINE AND CYCLOSPORINE IN HEART-TRANSPLANT RECIPIENTS", European Journal of Clinical Pharmacology, 53(1), 1997, pp. 39-45

Abstract

Objectives: Previous uncontrolled studies have suggested an interaction between ticlopidine, a major antiplatelet agent, and cyclosporin inheart-and kidney-transplant recipients. The aims of this study were to examine in a randomised, double-blind fashion, the possible interaction between cyclosporin A and ticlopidine (250 mg per day) and the tolerability of this combination in heart-transplant recipients. Methods:Twenty heart-transplant recipients were randomised into either a treated or a placebo group. Blood samples were drawn for time-course evaluation of cyclosporin blood levels over a period of 12 h, following themorning intake of cyclosporin and, for platelet aggregation studies, before and after 14 days of ticlopidine administration. Twenty four-hour urine samples were collected for 6-beta-hydroxycortisol measurements, before and after 14 days of ticlopidine. Results: Although given athalf the recommended daily dosage, ticlopidine significantly reduced platelet aggregation. Pharmacokinetic parameters indicate that the bioavailability of cyclosporin A was not significantly modified by ticlopidine. However, one patient in the ticlopidine group was withdrawn because of a major fall in cyclosporin blood level within 3 days of treatment. Urinary excretion of 6-beta-hydroxycortisol was augmented after treatment in the ticlopidine group compared with the placebo group, suggesting that induction of drug metabolism might have occurred. Data also show quite a large intra-individual variability in cyclosporin bioavailability in the placebo group, suggesting that poor absorption of the drug formulation and/or poor compliance might have contributed to the decreased cyclosporin blood levels in the patient withdrawn from this study and in previous uncontrolled studies. Conclusion: Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study. We, however, recommend closely monitoring cyclosporin blood levels when prescribing ticlopidine. Further studies will beneeded with new formulations of cyclosporin or when using the full dosage of ticlopidine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 01:44:28